Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?

Table 2 Management and prognosis of patients with the OSMC from 2010 to 2019

IDX	Surgery	Chemotherapy	PFS (months)	OS (months)
1	TAH + BSO + OM	None^b	NA^c	NA
2	TAH + BSO + OM	TP	96	96
3	TAH + BSO + OM	TO	91	91
4	TAH + BSO + OM	TO	88.5	88.5
5	TAH + BSO + OM	TC	78	78
6	TAH + BSO + OM + PEN	TC	10	11
7	TAH + BSO + OM	TP + IC + Doxorubicin	2.5	36
8	TAH + BSO + OM + PEN+PAN	TP	16	18
9	TAH + BSO + OM + PEN+PAN	TC	22	28
10	TAH + BSO + OM	None	NA	NA
11	TAH + BSO + OM + PEN+PAN	TP	38	38
12	LSO + OM + PAN^a	TP	17.5	17.5

ATH abdominal total hysterectomy, BSO bilateral salpingo-oophorectomy, LSO left salpingo-oophorectomy, OM omentectomy, PEN pelvic lymph node dissection, PAN para-aortic lymph node dissection, TC paclitaxel and carboplatin, DP docetaxel and carboplatin/ Cisplatin, DO docetaxel and oxaliplatin, TO paclitaxel and oxaliplatin, IC irinotecan and carboplatin
^a Fertility preserving surgery
^b No chemotherapy
^c loss to follow-up

ISSN: 1757-2215